Save Product
Product Details
Synonyms
CAIX, CA9, CA-IX, G250, MN, P54, 58N, pMW1
Source
Cynomolgus Carbonic Anhydrase IX Protein, His Tag (CA9-C52H3) is expressed from human 293 cells (HEK293). It contains AA Gln 38 - Leu 398 (Accession # A0A2K5VQG9-1).
Predicted N-terminus: Gln 38
Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 41.5 kDa. The protein migrates as 49-53 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in 25 mM MES, 100 mM NaCl, pH6.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Cynomolgus Carbonic Anhydrase IX Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
SEC-MALS
The purity of Cynomolgus Carbonic Anhydrase IX Protein, His Tag (Cat. No. CA9-C52H3) is more than 90% and the molecular weight of this protein is around 38-48 kDa verified by SEC-MALS.
Report
Bioactivity-SPR
Anti-Carbonic Anhydrase IX Antibody captured on Protein A Chip can bind Cynomolgus Carbonic Anhydrase IX Protein, His Tag (Cat. No. CA9-C52H3) with an affinity constant of 27.6 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Protocol
Bioactivity
The specific activity is >55 pmol/min/μg, as measured with 4-Nitrophenyl acetate (QC tested). One unit is defined as the amount of enzyme that hydrolyze 1.0 pmol of 4-Nitrophenyl acetate to 4-Nitrophenol per minute at pH7.5 at room temperature.
Protocol
Customer Reviews Writing Reviews
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
Background
Carbonic anhydrase 9 (CA9 / CAIX) is also known as Membrane antigen MN (MN), Renal cell carcinoma-associated antigen G250, which belongs to the alpha-carbonic anhydrase family. CA9 / CAIX with an optimal activity at pH 6.49. Reversible hydration of carbon dioxide. CA IX participates in pH regulation. CA9 may be involved in the control of cell proliferation and transformation. CA-IX appears to be a novel specific biomarker for a cervical neoplasia.
Recent Advances
Drug Development Progress- English Name：
Carbonic anhydrase IX
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
16 Details
- Highest Development Stage：
Phase 3 Clinical
Contact Us
Drug Candidate Licensing
